MCID: BRD004
MIFTS: 47

Borderline Personality Disorder malady

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

Aliases & Descriptions for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD10 33 F60.3
ICD9CM 35 301.83
MeSH 42 D001883
NCIt 47 C92633
SNOMED-CT 64 192488005 20010003
UMLS 69 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to personality disorder and antisocial personality disorder. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Neuroscience and Circadian rythm related genes. The drugs Citalopram and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and bone, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 71 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder, is a... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 personality disorder 31.0 BDNF COMT HTR1A HTR2A HTR2C MAOA
2 antisocial personality disorder 30.3 HTR1A HTR2A
3 schizophrenia 28.6 BDNF COMT HTR1A HTR1B HTR2A HTR2C
4 multiple personality disorder 27.5 AVPR1A BDNF COMT HTR1A HTR1B HTR2A
5 impulse control disorder 10.8
6 sexual sadism 10.8
7 bipolar disorder 10.2
8 conjunctival pigmentation 10.2 MAOA SLC6A4
9 cholestasis-lymphedema syndrome 10.2 COMT MAOA
10 chondrodysplasia lethal recessive 10.2 COMT TPH1
11 polyneuropathy 10.2 HTR1A HTR2A
12 aryepiglottic fold cancer 10.2 HTR1A HTR2A
13 ornithosis 10.2 MAOA SLC6A4
14 splenic abscess 10.2 HTR2A SLC6A4
15 nephronophthisis 13 10.2 COMT HTR2A SLC6A4
16 strongyloidiasis 10.2 COMT MAOA SLC6A4
17 apperceptive agnosia 10.2 COMT HTR1A SLC6A4
18 autism spectrum disorder 10.1 BDNF COMT SLC6A4
19 bulimia nervosa 10.1
20 adult brainstem astrocytoma 10.1 HTR1A MAOA SLC6A4
21 kidney pelvis papillary carcinoma 10.1 HTR1A MAOA SLC6A4
22 neurogenic bladder 10.1 HTR2A MAOA SLC6A4
23 teratoma with malignant transformation 10.1 BDNF HTR2A
24 tinea pedis 10.1 HTR1A MAOA SLC6A4
25 pyromania 10.1 HTR2A MAOA SLC6A4
26 euthyroid sick syndrome 10.1 HTR2A SLC6A4
27 substance dependence 10.1
28 attention deficit-hyperactivity disorder 10.1
29 hemochromatosis, type 2a 10.1 BDNF COMT MAOA
30 carotid stenosis 10.1 COMT MAOA SLC6A4 TPH1
31 bartter disease 10.0 HTR2A SLC6A4 TPH2
32 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.0 BDNF COMT HTR2A SLC6A4
33 basal cell carcinoma 3 10.0 COMT HTR2A MAOA TPH1
34 eating disorder 10.0
35 mood disorder 10.0
36 somatoform disorder 10.0
37 hepatitis b reinfection following liver transplantation 10.0 HTR1A HTR2A MAOA SLC6A4
38 mucinous adenocarcinoma 10.0 BDNF HTR1B MAOA SLC6A4
39 lethal congenital contracture syndrome 1 10.0 COMT MAOA
40 colorectal adenocarcinoma 10.0 COMT MAOA SLC6A4 TPH2
41 hypereosinophilic syndrome 10.0 BDNF HTR1B MAOA SLC6A4
42 parotid gland cancer 10.0 COMT HTR2A TPH1
43 cholesteatoma 10.0 BDNF COMT HTR2C SLC6A4
44 anxiety disorder 10.0
45 post-traumatic stress disorder 10.0
46 heroin dependence 10.0
47 alexithymia 10.0
48 epithelioid type angiomyolipoma 10.0 BDNF HTR2A SLC6A4
49 chronic eosinophilic pneumonia 9.9 BDNF COMT HTR1A MAOA SLC6A4
50 dry eye syndrome 9.9 HTR1A HTR2A HTR2C SLC6A4

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety Disorder
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

MGI Mouse Phenotypes related to Borderline Personality Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 AVPR1A BDNF COMT HTR1A HTR1B HTR2A
2 cardiovascular system MP:0005385 10.02 AVPR1A COMT HTR1A HTR1B MAOA NR3C1
3 homeostasis/metabolism MP:0005376 9.96 AVPR1A BDNF COMT HTR1A HTR2C MAOA
4 endocrine/exocrine gland MP:0005379 9.87 AVPR1A BDNF COMT HTR1B HTR2A NR3C1
5 integument MP:0010771 9.63 BDNF HTR2C NR3C1 SLC6A4 TPH1 TPH2
6 muscle MP:0005369 9.5 TPH1 AVPR1A HTR1B HTR2A HTR2C NR3C1
7 nervous system MP:0003631 9.28 AVPR1A BDNF COMT HTR1A HTR2C MAOA

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
2
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
3
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
6 Antidepressive Agents Phase 4,Phase 2
7 Antidepressive Agents, Second-Generation Phase 4,Phase 2
8 Antiparkinson Agents Phase 4,Phase 2
9 Autonomic Agents Phase 4,Phase 3,Phase 2
10 Cholinergic Agents Phase 4,Phase 2
11 Cholinergic Antagonists Phase 4,Phase 2
12 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Muscarinic Antagonists Phase 4,Phase 2
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
16 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
17 Parasympatholytics Phase 4,Phase 2
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
19 Psychotropic Drugs Phase 4,Phase 3,Phase 2
20
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
21 Serotonin Agents Phase 4,Phase 3,Phase 2
22 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
23 Antipsychotic Agents Phase 4,Phase 3,Phase 2
24 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
25 Dopamine Agents Phase 4,Phase 2
26 Dopamine Antagonists Phase 4,Phase 2
27 Serotonin Antagonists Phase 4,Phase 2
28 Tranquilizing Agents Phase 4,Phase 3,Phase 2
29 Anticonvulsants Phase 4,Phase 3
30 calcium channel blockers Phase 4
31 Calcium, Dietary Phase 4
32 Diuretics, Potassium Sparing Phase 4
33 Excitatory Amino Acid Antagonists Phase 4
34 Excitatory Amino Acids Phase 4
35 Sodium Channel Blockers Phase 4
36 Omega 3 Fatty Acid Nutraceutical Phase 4
37
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
38
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
39
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2 16590-41-3 5360515
40
Ethanol Approved Phase 3,Phase 2 64-17-5 702
41 Quetiapine Fumarate Phase 3,Phase 2 111974-72-2
42 Antiemetics Phase 3
43 Gastrointestinal Agents Phase 3
44 Narcotic Antagonists Phase 3,Phase 2
45 Narcotics Phase 3,Phase 2
46 Anti-Infective Agents Phase 3,Phase 2,Phase 1
47 Anti-Infective Agents, Local Phase 3,Phase 2
48 Protective Agents Phase 3,Phase 2,Phase 1
49
Oxytocin Approved, Vet_approved Phase 2,Phase 1 50-56-6 439302 53477758
50
Ziprasidone Approved Phase 2 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 133)
id Name Status NCT ID Phase
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4
2 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Unknown status NCT00834834 Phase 4
3 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4
4 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4
5 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4
6 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
7 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
8 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3
9 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3
10 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3
11 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Completed NCT00088036 Phase 3
12 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3
13 Naltrexone in Borderline Personality Disorder Terminated NCT00124839 Phase 3
14 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3
15 Ziprasidone in the Treatment of Borderline Personality Disorder Completed NCT00635921 Phase 2
16 Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment Completed NCT02125942 Phase 1, Phase 2
17 Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Completed NCT01103180 Phase 2
18 Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients Completed NCT00254748 Phase 2
19 Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder Completed NCT00145678 Phase 2
20 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2
21 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
22 Treatment of Suicidal Women With Borderline Personality Disorder Completed NCT00183651 Phase 2
23 Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders Completed NCT00247234 Phase 2
24 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2
25 Oxytocin as Adjunctive Therapy for Schizophrenia Completed NCT01699997 Phase 2
26 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
27 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2
28 A Novel Drug for Borderline Personality Disorder Recruiting NCT02097706 Phase 2
29 Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Recruiting NCT01212588 Phase 2
30 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2
31 Acetaminophen and Social Processes Active, not recruiting NCT02108990 Phase 2
32 N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Terminated NCT00539188 Phase 2
33 College Students Who Self-Harm Withdrawn NCT02522143 Phase 2
34 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
35 Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder Unknown status NCT00269139 Phase 1
36 20 Weeks DBT Group Skills Training Study Completed NCT01193205 Phase 1
37 Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents Completed NCT01111734 Phase 1
38 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1
39 Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Unknown status NCT01602497
40 Event Related Potentials in Borderline Personality Disorder and Major Depression Unknown status NCT01469663
41 Guanfacine to Treat Borderline Personality Disorder Unknown status NCT00358969
42 Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention Unknown status NCT01531634
43 Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder Unknown status NCT00131781
44 A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder Unknown status NCT01033708
45 DBT in Borderline Personality Disorder Unknown status NCT00252031
46 A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults Unknown status NCT01426984
47 DBT and Escitalopram in Borderline Personality Disorder Unknown status NCT00255554
48 Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder Unknown status NCT01683136
49 "The Effects of Oxytocin on Patients With Borderline Personality Disorder" Unknown status NCT01243658
50 Intensified, Inpatient Adaptation of Dialectical Behavior Therapy (DBT) Unknown status NCT01904227

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

39
Brain, Amygdala, Bone, Testes, Pituitary, Cortex, Ovary

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 700)
id Title Authors Year
1
The specificity of emotion dysregulation in adolescents with borderline personality disorder: comparison with psychiatric and healthy controls. ( 28078089 )
2017
2
Altered Empathy for Psychological and Physical Pain in Borderline Personality Disorder. ( 28072040 )
2017
3
Compelled to Risk: Does Sexual Compulsivity Explain the Connection Between Borderline Personality Disorder Features and Number of Sexual Partners? ( 28072043 )
2017
4
Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. ( 28086181 )
2017
5
A Mother's Borderline Personality Disorder and Her Sensitivity, Autonomy Support, Hostility, Fearful/Disoriented Behavior, and Role Reversal With Her Young Child. ( 28072039 )
2017
6
Insomnia in adult attention-deficit/hyperactivity disorder: A comparison with borderline personality disorder population in a clinical setting and control participants. ( 28501733 )
2017
7
Predicting Nonsuicidal Self-Injury in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 28072044 )
2017
8
Resting cardiac function in adolescent non-suicidal self-injury: The impact of borderline personality disorder symptoms and psychosocial functioning. ( 28039803 )
2017
9
Interpersonal Threat Sensitivity in Borderline Personality Disorder: An Eye-Tracking Study. ( 28072041 )
2017
10
Comorbidity study of borderline personality disorder: applying association rule mining to the Taiwan national health insurance research database. ( 28077135 )
2017
11
Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. ( 27144298 )
2016
12
Cognitive and affective processing of social exclusion in borderline personality disorder and social anxiety disorder. ( 27616717 )
2016
13
Creativity and borderline personality disorder: evidence from a voxel-based morphometry study. ( 27174566 )
2016
14
A Neurobiological Model of Borderline Personality Disorder: Systematic and Integrative Review. ( 27603741 )
2016
15
Evidence-Based Treatments for Borderline Personality Disorder: Implementation, Integration, and Stepped Care. ( 27603742 )
2016
16
Long-Term Course of Borderline Personality Disorder. ( 27603806 )
2016
17
Deficient amygdala-prefrontal intrinsic connectivity after effortful emotion regulation in borderline personality disorder. ( 28039553 )
2016
18
Borderline Personality Disorder and the Effects of Instructed Emotional Avoidance or Acceptance in Daily Life. ( 27617652 )
2016
19
Borderline Personality Disorder Symptoms in College Students: The Complex Interplay between Alexithymia, Emotional Dysregulation and Rumination. ( 27348858 )
2016
20
Comparing the experience of voices in borderline personality disorder with the experience of voices in a psychotic disorder: A systematic review. ( 26912339 )
2016
21
Biting the hand that feeds: current opinion on the interpersonal causes, correlates, and consequences of borderline personality disorder. ( 27990277 )
2016
22
The role of hypothalamus-pituitary-adrenal genes and childhood trauma in borderline personality disorder. ( 26182893 )
2016
23
Sleep Problems in Childhood and Borderline Personality Disorder Symptoms in Early Adolescence. ( 27108717 )
2016
24
Association between schizotypal and borderline personality disorder traits, and cannabis use in young adults. ( 27149691 )
2016
25
Alcohol Craving and Consumption in Borderline Personality Disorder: When, Where, and with Whom. ( 28042520 )
2016
26
Skills use and common treatment processes in dialectical behaviour therapy for borderline personality disorder. ( 27132175 )
2016
27
An Investigation into the Roles of Theory of Mind, Emotion Regulation, and Attachment Styles in Predicting the Traits of Borderline Personality Disorder. ( 28050180 )
2016
28
Preliminary Evidence for Emotion Dysregulation as a Mechanism Underlying Poor Sleep Quality in Borderline Personality Disorder. ( 27617649 )
2016
29
Attentional Bias for Emotional Stimuli in Borderline Personality Disorder: A Meta-Analysis. ( 27642753 )
2016
30
Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data. ( 27990594 )
2016
31
Object Relations Predicts Borderline Personality Disorder Symptoms Beyond Emotional Dysregulation, Negative Affect, and Impulsivity. ( 27176498 )
2016
32
Borderline Personality Disorder in the Emergency Department: Good Psychiatric Management. ( 27603743 )
2016
33
A new intervention for people with borderline personality disorder who are also parents: a pilot study of clinician acceptability. ( 27617096 )
2016
34
Borderline personality disorder, but not euthymic bipolar I disorder, is associated with prolonged post-error slowing in sensorimotor performance. ( 27016660 )
2016
35
The two-faceted nature of impulsivity in patients with borderline personality disorder and substance use disorder. ( 27107850 )
2016
36
Mentalization-based therapy adherence and competence stimulates in-session mentalization in psychotherapy for borderline personality disorder with co-morbid substance dependence. ( 27093128 )
2016
37
Impulsivity and aggression mediate regional brain responses in Borderline Personality Disorder: An fMRI study. ( 28039797 )
2016
38
Outcome Uncertainty and Brain Activity Aberrance in the Insula and Anterior Cingulate Cortex Are Associated with Dysfunctional Impulsivity in Borderline Personality Disorder. ( 27199724 )
2016
39
Prevalence of Borderline Personality Disorder in University Samples: Systematic Review, Meta-Analysis and Meta-Regression. ( 27171206 )
2016
40
Borderline personality disorder and compulsive buying: A multivariate etiological model. ( 27124503 )
2016
41
Interpersonal emotion regulation in Asperger's syndrome and borderline personality disorder. ( 27990657 )
2016
42
Anxious adult attachment may mediate the relationship between childhood emotional abuse and borderline personality disorder. ( 27604841 )
2016
43
The impact of stimulus arousal level on emotion regulation effectiveness in borderline personality disorder. ( 27203152 )
2016
44
Abnormal white matter structural connectivity in treatment-naA^ve young adults with borderline personality disorder. ( 27611589 )
2016
45
The association of posttraumatic stress disorder, complex posttraumatic stress disorder, and borderline personality disorder from a network analytical perspective. ( 27637074 )
2016
46
Is There a Relationship Between Borderline Personality Disorder and Sexual Masochism in Women? ( 27600835 )
2016
47
Suicidality and hospitalisation in patients with borderline personality disorder who experience auditory verbal hallucinations. ( 28049081 )
2016
48
Aberrant DNA Methylation of rDNA and PRIMA1 in Borderline Personality Disorder. ( 26742039 )
2016
49
Use of Clozapine for Borderline Personality Disorder: A Case Report. ( 27121437 )
2016
50
The Main and Interactive Effects of Maternal Interpersonal Emotion Regulation and Negative Affect on Adolescent Girls' Borderline Personality Disorder Symptoms. ( 27185969 )
2016

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1 12.24 COMT HTR1A TPH1 TPH2
3
Show member pathways
12.02 BDNF HTR1A HTR1B
4
Show member pathways
11.97 AVPR1A HTR2A HTR2C
5 11.97 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
6
Show member pathways
11.93 MAOA TPH1 TPH2
7
Show member pathways
11.68 HTR1A HTR1B HTR2A HTR2C
8 11.61 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
9
Show member pathways
11.21 MAOA SLC6A4 TPH2
10
Show member pathways
10.98 COMT MAOA SLC6A4
11 10.8 HTR2A HTR2C
12
Show member pathways
10.78 COMT MAOA TPH1
13 10.67 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
14 10.62 COMT MAOA
15
Show member pathways
10.6 COMT MAOA

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 AVPR1A HTR1A HTR1B HTR2A HTR2C NRXN3

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.85 HTR1B HTR2A HTR2C NRXN3
2 circadian rhythm GO:0007623 9.77 SLC6A4 TPH1 TPH2
3 response to drug GO:0042493 9.77 COMT HTR1B HTR2A HTR2C SLC6A4
4 social behavior GO:0035176 9.67 AVPR1A NRXN3 SLC6A4
5 positive regulation of fat cell differentiation GO:0045600 9.65 HTR2A HTR2C TPH1
6 release of sequestered calcium ion into cytosol GO:0051209 9.64 HTR2A HTR2C
7 positive regulation of vasoconstriction GO:0045907 9.63 AVPR1A HTR2A
8 behavioral fear response GO:0001662 9.63 HTR1A HTR2C
9 activation of phospholipase C activity GO:0007202 9.62 AVPR1A HTR2A
10 regulation of dopamine secretion GO:0014059 9.62 HTR1B HTR2A
11 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 HTR1B HTR2A
12 bone remodeling GO:0046849 9.6 HTR1B TPH1
13 neurotransmitter catabolic process GO:0042135 9.58 COMT MAOA
14 catecholamine metabolic process GO:0006584 9.58 COMT MAOA
15 dopamine catabolic process GO:0042420 9.57 COMT MAOA
16 aromatic amino acid family metabolic process GO:0009072 9.56 TPH1 TPH2
17 sperm ejaculation GO:0042713 9.54 AVPR1A SLC6A4
18 regulation of hormone secretion GO:0046883 9.52 HTR1A HTR2A
19 indolalkylamine biosynthetic process GO:0046219 9.51 TPH1 TPH2
20 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.46 HTR1A HTR1B
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.43 HTR2A HTR2C
22 vasoconstriction GO:0042310 9.43 HTR1A HTR1B SLC6A4
23 serotonin biosynthetic process GO:0042427 9.4 TPH1 TPH2
24 regulation of behavior GO:0050795 9.33 HTR1A HTR1B HTR2A
25 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.32 HTR2A HTR2C
26 serotonin receptor signaling pathway GO:0007210 9.13 HTR1A HTR2A HTR2C
27 behavior GO:0007610 8.92 HTR1A HTR1B HTR2A HTR2C
28 signal transduction GO:0007165 10.16 AVPR1A HTR1A HTR1B HTR2A HTR2C NR3C1
29 G-protein coupled receptor signaling pathway GO:0007186 10.04 AVPR1A HTR1A HTR1B HTR2A HTR2C

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.85 AVPR1A HTR1A HTR1B HTR2A HTR2C
2 signal transducer activity GO:0004871 9.77 AVPR1A HTR1A HTR1B HTR2A HTR2C
3 drug binding GO:0008144 9.61 HTR1B HTR2A HTR2C
4 amino acid binding GO:0016597 9.48 TPH1 TPH2
5 G-protein coupled serotonin receptor activity GO:0004993 9.46 HTR1A HTR1B HTR2A HTR2C
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.4 TPH1 TPH2
7 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.32 HTR2A HTR2C
8 tryptophan 5-monooxygenase activity GO:0004510 9.26 TPH1 TPH2
9 neurotransmitter receptor activity GO:0030594 9.26 HTR1A HTR1B HTR2A HTR2C
10 serotonin binding GO:0051378 8.92 HTR1A HTR1B HTR2A HTR2C

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....